AptarGroup Says Its Proprietary Nasal Delivery System Is Utilized In LTR Pharma's Phase II Clinical Study Of SPONTAN, Investigational Intranasal Spray Under Development For Treatment Of Erectile Dysfunction - AptarGroup (NYSE:ATR)
Published on March 16, 2026.
AptarGroup's Proprietary Nasal Delivery System is being used in LTR Pharma's Phase II Clinical Study of SPONTAN, an Investigational Intranasal Spray, under consideration for its treatment of Erectile Dysfunction. The company's innovative system is being tested for its effectiveness in helping to combat this disease.
Related Articles
Nvidia (NVDA) news: CEO Jensen Huang's keynote fuels AI crypto token rally
Nvidia CEO Jensen Huang's keynote led to a significant spike in AI crypto tokens, with major gains occurring in FET and S. Christ Christ Christ."
Veteran analyst warns markets mirror 2008 amid Iran war
Mike McGlone warns that the Iran war could trigger a market downturn, causing significant volatility in energy, precious metals, and crypto markets.
Stock futures are little changed after major averages rebound on cooler oil prices: Live updates
Stock futures were little changed as oil prices eased, but gains in tech stocks and earnings outweighed declines in other sectors, raising investor concerns about economic growth and the Iran war.